A hexavalent Coxsackievirus B vaccine is highly immunogenic and has a strong protective capacity in mice and nonhuman primates-Reference-Cited by-同舟云学术

A hexavalent Coxsackievirus B vaccine is highly immunogenic and has a strong protective capacity in mice and nonhuman primates

Published:2020-05-08 Issue:19 Volume:6 Page:
ISSN:2375-2548
Container-title:Science Advances
language:en
Short-container-title:Sci. Adv.

Author:

Stone V. M.¹²^ORCID,Hankaniemi M. M.²^ORCID,Laitinen O. H.²^ORCID,Sioofy-Khojine A. B.²^ORCID,Lin A.³^ORCID,Diaz Lozano I. M.¹,Mazur M. A.¹,Marjomäki V.⁴,Loré K.³^ORCID,Hyöty H.²⁵^ORCID,Hytönen V. P.²⁵^ORCID,Flodström-Tullberg M.¹²^ORCID

Affiliation:

1. Center for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.

2. Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.

3. Division of Immunology and Allergy, Department of Medicine Solna, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.

4. Department of Biological and Environmental Science/Nanoscience Center, University of Jyväskylä, Jyväskylä, Finland.

5. Fimlab Laboratories, Tampere, Finland.

Abstract

A proof-of-concept study shows the generation of an immunogenic hexavalent Coxsackie B virus vaccine that prevents disease.

Funder

Business Finland

the Swedish Child Diabetes Foundation

Karolinska Institutet including the Strategic Research Program in Diabetes

Publisher

American Association for the Advancement of Science (AAAS)

Subject

Multidisciplinary

Reference42 articles.

1. Enterovirus and Parechovirus Surveillance — United States, 2014–2016

2. Detection and typing of enteroviruses from CSF specimens from patients diagnosed with meningitis/encephalitis

3. Pathogenesis of coxsackievirus B2 in mice: characterization of clinical isolates of the coxsackievirus B2 from patients with myocarditis and aseptic meningitis in Korea

4. Update on coxsackievirus B3 myocarditis

5. Viral myocarditis—diagnosis, treatment options, and current controversies

Cited by 59 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Enteroviruses: epidemic potential, challenges and opportunities with vaccines;Journal of Biomedical Science;2024-07-15

2. Comparison of structure and immunogenicity of CVB1-VLP and inactivated CVB1 vaccine candidates;2024-06-28

3. Immunogenicity and protective efficacy of inactivated coxsackievirus B4 viral particles;Emerging Microbes & Infections;2024-04-05

4. Coxsackievirus infection induces direct pancreatic β cell killing but poor antiviral CD8 ⁺ T cell responses;Science Advances;2024-03-08

5. Safety, tolerability and immunogenicity of PRV-101, a multivalent vaccine targeting coxsackie B viruses (CVBs) associated with type 1 diabetes: a double-blind randomised placebo-controlled Phase I trial;Diabetologia;2024-02-19